VTX:NOVN - Novartis Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
CHF 78.38 +0.34 (+0.44 %)
(As of 10/23/2018 09:58 AM ET)
Previous CloseCHF 78.36
Today's RangeCHF 77.72 - CHF 78.50
52-Week RangeCHF 72.45 - CHF 88.30
Volume11.21 million shs
Average Volume5.98 million shs
Market Capitalization$206.54 billion
P/E RatioN/A
Dividend Yield3.57%
BetaN/A
Novan, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum. The company's clinical stage product candidates comprise SB208, a topical antifungal gel that is in Phase II proof-of-concept trial for the treatment of athlete's foot and fungal nail infections; and SB414, a topical cream, which is in Phase Ib trial for the treatment of inflammatory skin diseases, such as psoriasis and atopic dermatitis. It has a license agreement with Sato Pharmaceutical Co., Ltd. Novan, Inc. was founded in 2006 and is headquartered in Morrisville, North Carolina.

Receive NOVN News and Ratings via Email

Sign-up to receive the latest news and ratings for NOVN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange VTX
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolVTX:NOVN
CUSIPN/A
Phone+41-61-3241111

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins15.47%
Return on Equity11.16%
Return on Assets6.10%

Miscellaneous

EmployeesN/A
Outstanding Shares2,330,000,000
Market Cap$206.54 billion

Novartis (VTX:NOVN) Frequently Asked Questions

What is Novartis' stock symbol?

Novartis trades on the VTX under the ticker symbol "NOVN."

What price target have analysts set for NOVN?

20 brokerages have issued 12 month target prices for Novartis' stock. Their predictions range from CHF 79 to CHF 100. On average, they anticipate Novartis' share price to reach CHF 89.25 in the next year. This suggests a possible upside of 13.9% from the stock's current price. View Analyst Price Targets for Novartis.

What is the consensus analysts' recommendation for Novartis?

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 11 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novartis.

Who are some of Novartis' key competitors?

Who are Novartis' key executives?

Novartis' management team includes the folowing people:
  • Mr. G. Kelly Martin, CEO & Director (Age 59)
  • Dr. Nathan Stasko, Co-Founder, Pres, Chief Scientific Officer & Director (Age 38)
  • Mr. Jeff N. Hunter, Exec. VP, Chief Bus. Officer & Company Sec. (Age 61)
  • Ms. Paula Brown Stafford, Chief Devel. Officer & Director (Age 53)
  • Mr. Andrew Novak, VP & Chief Accounting Officer

What is Novartis' stock price today?

One share of NOVN stock can currently be purchased for approximately CHF 78.38.

How big of a company is Novartis?

Novartis has a market capitalization of $206.54 billion.

What is Novartis' official website?

The official website for Novartis is https://www.novartis.com/.

How can I contact Novartis?

Novartis' mailing address is Lichtstrasse 35, BASEL, 4056, Switzerland. The company can be reached via phone at +41-61-3241111.


MarketBeat Community Rating for Novartis (VTX NOVN)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  161 (Vote Outperform)
Underperform Votes:  201 (Vote Underperform)
Total Votes:  362
MarketBeat's community ratings are surveys of what our community members think about Novartis and other stocks. Vote "Outperform" if you believe NOVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NOVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel